MORE►
MCO-010
Allen C. Ho, MD [Photo: Nanoscope Therapeutics]
Nanoscope Therapeutics Appoints New Chief Medical Officer
by Lance Murray | Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
by Lance Murray |
Oct 27, 2023
Najam Sharif, Ph.D., DSc, has been appointed as vice president of global research and development by Dallas-based Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases.
Sharif is a veteran in drug/device discovery and development, the company said.
“We are delighted to welcome Naj to the Nanoscope team,” Sulagna Bhattacharya, co-founder and CEO of Nanoscope, said in a statement....
MORE►
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
